Idexx Laboratories (IDXX) Current Deferred Revenue (2009 - 2026)

Idexx Laboratories' Current Deferred Revenue history runs 18 years deep, the most recent figure standing at $36.3 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 3.79% year-over-year to $36.3 million; the TTM figure through Mar 2026 stood at $36.3 million (up 3.79% YoY), while the FY2025 annual figure was $35.3 million, up 4.33% from the prior year.
• Current Deferred Revenue was $36.3 million for Q1 2026 at Idexx Laboratories, up from $35.3 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $40.9 million in Q1 2022 to a low of $33.8 million in Q4 2024.
• Historically, Current Deferred Revenue has averaged $37.5 million across 5 years, with a median of $37.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue declined 9.13% in 2024, then gained 4.33% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $37.9 million in 2022, then fell by 1.96% to $37.2 million in 2023, then fell by 9.13% to $33.8 million in 2024, then gained by 4.33% to $35.3 million in 2025, then grew by 3.02% to $36.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $36.3 million (Q1 2026), $35.3 million (Q4 2025), and $35.7 million (Q3 2025), per Business Quant data.